Combined JAK2 and HSP90 inhibition produces synergistic anti-tumour activity across preclinical glioblastoma models
Background: Glioblastoma (GBM) remains difficult to treat because of tumour heterogeneity and the limited activity of single-target therapies. Our previous phenotypic drug screen identified JAK2/STAT3 signalling and HSP90-dependent protein homeostasis as pharmacological vulnerabilities. We investigated whether combined JAK2 and HSP90 inhibition could produce broader anti-tumour activity across GBM models. Methods: Multiple JAK2 and HSP90 inhibitors were tested alone and in combination across 2- and 3-dimensional patient-derived GBM stem cell models. Drug interactions were quantified using the zero-interaction potency (ZIP) synergy model. Mechanistic studies included RNA sequencing, flow cytometry, western blotting, immunofluorescence and FUCCI live-cell imaging. Activity was also assessed in cerebral organoid GBM co-cultures, non-malignant human neural and glial cells and orthotopic GBM xenografts. Results: Combined JAK2 and HSP90 inhibition produced synergistic interactions in 12 of the 13 GBM cell lines tested, using multiple structurally distinct inhibitor pairs. Gandotinib and NMS-E973 were selected for further mechanistic studies, where the combination reduced spheroid growth and increased caspase-3 activation and PARP cleavage. Combination treatment was associated with G2/M accumulation, altered mitotic regulation, abnormal chromosome and spindle organisation, and increased gamma-H2AX signalling. Anti-tumour combination activity was maintained in cerebral organoid co-cultures, where tumour burden was reduced as assessed by imaging, histological and luciferase-based measurements, while the drug combination had relatively limited effects on non-malignant human neural and glial cell types tested over the same concentration range. In vivo, combined Pacritinib and NMS-E973 treatment significantly reduced tumour burden in orthotopic G7 xenografts compared with vehicle or either single agent. Conclusions: JAK2/HSP90 co-inhibition produces reproducible anti-tumour activity across heterogeneous GBM models and disrupts cell-cycle and mitotic progression. These findings support further evaluation of this combination strategy in GBM.
Authors
- Alexander E.P. Loftus (ORCID: https://orcid.org/0000-0002-0013-1532)
- Vanessa Smer-Barreto (ORCID: https://orcid.org/0009-0009-1455-1261)
- Valerie G. Brunton (ORCID: https://orcid.org/0000-0002-7778-8794)
- Margaret C. Frame (ORCID: https://orcid.org/0000-0001-5882-1942)
- Bhuvaneish Thangaraj Selvaraj (ORCID: https://orcid.org/0000-0001-7299-0910)
- Morwenna Muir (ORCID: https://orcid.org/0000-0001-5835-3886)
- Fraser Laing
- Steven M. Pollard (ORCID: https://orcid.org/0000-0001-6428-0492)
- John C. Dawson (ORCID: https://orcid.org/0000-0001-5713-1026)
- Alison F. Munro (ORCID: https://orcid.org/0000-0001-5345-5816)
- Neil O. Carragher (ORCID: https://orcid.org/0000-0001-5541-9747)
- Camilla Drake (ORCID: https://orcid.org/0009-0003-0089-2571)
- Wai Kit Chan (ORCID: https://orcid.org/0000-0002-8097-0802)
- Roza H. Ali Masalmeh (ORCID: https://orcid.org/0000-0002-6079-5066)
- Peter W. Nagle (ORCID: https://orcid.org/0000-0001-6150-2571)
- John O. Mason (ORCID: https://orcid.org/0000-0002-0489-2400)
- Roderick N. Carter (ORCID: https://orcid.org/0000-0001-6565-9939)
- Muhammad Furqan (ORCID: https://orcid.org/0009-0003-8459-5880)
- Gillian M. Morrison
- Richard J. R. Elliott (ORCID: https://orcid.org/0009-0002-0174-5488)
- Martin Lee
- Paul Baxter
Institutions
- University of Edinburgh (GB)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.64898/2026.11.18.767500
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- preprint